Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal document ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their IL-2 and IL-13 inhibitor Dupixent (dupilumab) last year – GSK has ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...